Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10183185 | 0.82 | PKM (0.32) | — | |
| SCHEMBL11916149 | 0.78 | SLC6A2 (0.38) | KDM4EALDH1A1MAPTHTTSLC6A2 | |
| SCHEMBL4680982 | 0.78 | MAPT (0.39) | MAPTHTTSLC6A4FFAR4 | |
| SCHEMBL13088048 | 0.76 | — | — | |
| SCHEMBL17110495 | 0.76 | — | — | |
| SCHEMBL17110601 | 0.75 | — | — | |
| SCHEMBL14723884 | 0.75 | SHBG (0.31) | — | |
| SCHEMBL24710092 | 0.74 | DPP4 (0.35) | KDM4EALDH1A1MAPTHTTSLC6A2 | |
| SCHEMBL9339058 | 0.72 | ALDH1A1 (0.35) | KDM4EALDH1A1MAPTHTT | |
| SCHEMBL22541481 | 0.72 | MAPT (0.40) | KDM4EALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364251-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | CIDARA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2022133281-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364251-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | DNPEP, NPEPPS, DHFR | KDM4E 2941/4885ALDH1A1 1379/4885MAPT 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.